Allogene Takes Step Closer To Off-The-Shelf CAR-Ts
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
You may also be interested in...
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches.
Former Kite exec David Chang is keen to use smaller firm's focus to advance allogeneic therapy more rapidly. The start-up acquired Pfizer R&D team along with its allogeneic CAR-T programs and related IP.